Current treatment of rectal cancer adapted to the individual patient

Reports of Practical Oncology and Radiotherapy

Volumn 18, Issue 6, 2013, Pages 353-362

  Cerezo, Laura ^a   Ciria, Juan Pablo ^b   Arbea, Leire ^c   Liñán, Olga ^a   Cafiero, Sergio ^b   Valentini, Vincenzo ^d   Cellini, Francesco ^e  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL DONOSTIA   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

^d FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^e UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Individualized treatment; Preoperative radiotherapy; Rectal cancer

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER SURGERY; CANCER THERAPY; CHEMORADIOTHERAPY; COLORECTAL ANASTOMOSIS; DIARRHEA; DISEASE FREE SURVIVAL; GASTROINTESTINAL TOXICITY; GENE EXPRESSION; HUMAN; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PREOPERATIVE RADIOTHERAPY; PROCTITIS; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; RECTUM ABDOMINOPERINEAL RESECTION; RECTUM ANTERIOR RESECTION; RECTUM CANCER; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION;

EID: 84888303620     PISSN: 15071367     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rpor.2013.08.005     Document Type: Review

References (59)

1. NIH consensus conference Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990, 264(SEPTEMBER (11)):1444-1450.
2. Preoperative short-term radiation therapy in operable rectal carcinoma A prospective randomized trial. Stockholm Rectal Cancer Study Group. Cancer 1990, 66(July (1)):49-55.
3. Glynne-Jones R., Wallace M., Livingstone J.I., Meyrick-Thomas J. Complete clinical response after preoperative chemoradiation in rectal cancer: is a "wait and see" policy justified?. Dis Colon Rectum 2008, 51(January (1)):10-19.
4. Glimelius B., Gronberg H., Jarhult J., Wallgren A., Cavallin-Stahl E. A systematic overview of radiation therapy effects in rectal cancer. Acta Oncol 2003, 42(5/6):476-492.
5. Bujko K., Nowacki M.P., Nasierowska-Guttmejer A., Michalski W., Bebenek M., Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006, 93(October (10)):1215-1223.
6. Gerard J.P., Azria D., Gourgou-Bourgade S., et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol 2012, 30(December (36)):4558-4565.
7. Gerard J.P., Chapet O., Nemoz C., et al. Improved sphincter preservation in low rectal cancer with high-dose preoperative radiotherapy: the lyon R96-02 randomized trial. J Clin Oncol 2004, 22(June (12)):2404-2409.
8. Ortholan C., Romestaing P., Chapet O., Gerard J.P. Correlation in rectal cancer between clinical tumor response after neoadjuvant radiotherapy and sphincter or organ preservation: 10-year results of the Lyon R 96-02 randomized trial. Int J Radiat Oncol Biol Phys 2012, 83(June (2)):e165-e171.
9. Improved survival with preoperative radiotherapy in resectable rectal cancer Swedish Rectal Cancer Trial. N Engl J Med 1997, 336(April (14)):980-987.
10. Peeters K.C., Marijnen C.A., Nagtegaal I.D., et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007, 246(November (5)):693-701.
11. Sauer R., Liersch T., Merkel S., et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 2012, 30(June (16)):1926-1933.
12. Roh M.S., Colangelo L.H., O'Connell M.J., et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 2009, 27(November (31)):5124-5130.
13. Park J.H., Yoon S.M., Yu C.S., Kim J.H., Kim T.W., Kim J.C. Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancer. Cancer 2011, 117(AUGUST (16)):3703-3712.
14. NCCN clinical practice guidelines in oncology: rectal cancer. (Version 4.2013) 2013, http://www.nccn org/professionals/physician_gls/f_guidelines asp#rectal.
15. NCI. National Cancer Institute PDQ Rectal Cancer Treatment 2013, National Cancer Institute, Bethesda, MD, Available at: http://cancergov/cancertopics/pdq/treatment/rectal/HealthProfessional [last modified 02.08.13].
16. Valentini V., Aristei C., Glimelius B., et al. Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2). Radiother Oncol 2009, 92(AUGUST (2)):148-163.
17. Guillem J.G., az-Gonzalez J.A., Minsky B.D., et al. cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted. J Clin Oncol 2008, 26(January (3)):368-373.
18. Nagtegaal I.D., Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer?. J Clin Oncol 2008, 26(January (2)):303-312.
19. Allal A.S., Bieri S., Pelloni A., et al. Sphincter-sparing surgery after preoperative radiotherapy for low rectal cancers: feasibility, oncologic results and quality of life outcomes. Br J Cancer 2000, 82(March (6)):1131-1137.
20. Sauer R., Becker H., Hohenberger W., et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004, 351(October (17)):1731-1740.
21. Capirci C., Valentini V., Cionini L., et al. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys 2008, 72(SEPTEMBER (1)):99-107.
22. Mihaylova I., Parvanova V., Velikova C., Kurteva G. Degree of tumor regression after preoperative chemo-radiotherapy in locally advanced rectal cancer - preliminary results. Rep Pract Oncol Radiother 2011, 16(237):242.
23. Valentini V., van Stiphout R.G., Lammering G., et al. Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol 2011, 29(AUGUST (23)):3163-3172.
24. Cellini F., Valentini V. Sphincter preservation in the treatment of locally advanced rectal cancers. Oncology (Williston Park) 2012, 26(SEPTEMBER (9)):872.
25. Bosset J.F., Calais G., Mineur L., et al. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results - EORTC 22921. J Clin Oncol 2005, 23(AUGUST (24)):5620-5627.
26. Braendengen M., Tveit K.M., Berglund A., et al. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol 2008, 26(AUGUST (22)):3687-3694.
27. Hofheinz R.D., Wenz F., Post S., et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 2012, 13(June (6)):579-588.
28. Conde S., Borrego M., Teixeira T., Teixeira R., SA A., Soares P. Neoadjuvant oral VS infusional chemoradiotherapy on locally advanced rectal câncer: prognostic factors. Rep Pract Oncol Radiother 2013, 18(67):75.
29. Aschele C., Cionini L., Lonardi S., et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 2011, 29(July (20)):2773-2780.
30. Gerard J.P., Azria D., Gourgou-Bourgade S., et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 2010, 28(April (10)):1638-1644.
31. Rodel C., Liersch T., Becker H., et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 2012, 13(July (7)):679-687.
32. Ngan S.Y., Burmeister B., Fisher R.J., et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 2012, 30(November (31)):3827-3833.
33. Pettersson D., Cedermark B., Holm T., et al. Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer. Br J Surg 2010, 97(April (4)):580-587.
34. Pettersson D., Glimelius B., Iversen H., Johansson H., Holm T., Martling A. Impaired postoperative leucocyte counts after preoperative radiotherapy for rectal cancer in the Stockholm III Trial. Br J Surg 2013, 100(April (7)):969-975.
35. Radu C., Berglund A., Pahlman L., Glimelius B. Short-course preoperative radiotherapy with delayed surgery in rectal cancer - a retrospective study. Radiother Oncol 2008, 87(June (3)):343-349.
36. Hatfield P., Hingorani M., Radhakrishna G., et al. Short-course radiotherapy, with elective delay prior to surgery, in patients with unresectable rectal cancer who have poor performance status or significant co-morbidity. Radiother Oncol 2009, 92(AUGUST (2)):210-214.
37. Gerard J.P., Roy P., Coquard R., et al. Combined curative radiation therapy alone in (T1) T2-3 rectal adenocarcinoma: a pilot study of 29 patients. Radiother Oncol 1996, 38(February (2)):131-137.
38. Gerard J.P., Ortholan C., Benezery K., et al. Contact X-ray therapy for rectal cancer: experience in Centre Antoine-Lacassagne, Nice, 2002-2006. Int J Radiat Oncol Biol Phys 2008, 72(November (3)):665-670.
39. Habr-Gama A., de Souza P.M., Ribeiro U., et al. Low rectal cancer: impact of radiation and chemotherapy on surgical treatment. Dis Colon Rectum 1998, 41(SEPTEMBER (9)):1087-1096.
40. Habr-Gama A., Perez R.O., Proscurshim I., et al. Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy. J Gastrointest Surg 2006, 10(December (10)):1319-1328.
41. Papillon J. Present status of radiation therapy in the conservative management of rectal cancer. Radiother Oncol 1990, 17(April (4)):275-283.
42. Maas M., Beets-Tan R.G., Lambregts D.M., et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol 2011, 29(December (35)):4633-4640.
43. Patel U.B., Brown G., Rutten H., et al. Comparison of magnetic resonance imaging and histopathological response to chemoradiotherapy in locally advanced rectal cancer. Ann Surg Oncol 2012, 19(SEPTEMBER (9)):2842-2852.
44. O'Connell M.J., Martenson J.A., Wieand H.S., et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994, 331(AUGUST (8)):502-507.
45. Baglan K.L., Frazier R.C., Yan D., Huang R.R., Martinez A.A., Robertson J.M. The dose-volume relationship of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys 2002, 52(January (1)):176-183.
46. Gunnlaugsson A., Kjellen E., Nilsson P., Bendahl P.O., Willner J., Johnsson A. Dose-volume relationships between enteritis and irradiated bowel volumes during 5-fluorouracil and oxaliplatin based chemoradiotherapy in locally advanced rectal cancer. Acta Oncol 2007, 46(7):937-944.
47. Robertson J.M., Lockman D., Yan D., Wallace M. The dose-volume relationship of small bowel irradiation and acute grade 3 diarrhea during chemoradiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 2008, 70(February (2)):413-418.
48. Tho L.M., Glegg M., Paterson J., et al. Acute small bowel toxicity and preoperative chemoradiotherapy for rectal cancer: investigating dose-volume relationships and role for inverse planning. Int J Radiat Oncol Biol Phys 2006, 66(October (2)):505-513.
49. Nijkamp J., Kusters M., Beets-Tan R.G., et al. Three-dimensional analysis of recurrence patterns in rectal cancer: the cranial border in hypofractionated preoperative radiotherapy can be lowered. Int J Radiat Oncol Biol Phys 2011, 80(May (1)):103-110.
50. Myerson R.J., Garofalo M.C., El Naqa I., et al. Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring Atlas. Int J. Radiat Oncol Biol Phys 2009, 74(July (3)):824-830.
51. Arbea L., Ramos L.I., Martinez-Monge R., Moreno M., Aristu J. Intensity-modulated radiation therapy (IMRT) vs. 3D conformal radiotherapy (3DCRT) in locally advanced rectal cancer (LARC): dosimetric comparison and clinical implications. Radiat Oncol 2010, 5:17.
52. Callister M.D., Ezzell G.A., Gunderson L.L. IMRT reduces the dose to small bowel and other pelvic organs in the preoperative treatment of rectal cancer. Int J Radiat Oncol Biol Phys 2006, 66(3):S290.
53. Guerrero Urbano M.T., Henrys A.J., Adams E.J., et al. Intensity-modulated radiotherapy in patients with locally advanced rectal cancer reduces volume of bowel treated to high dose levels. Int J Radiat Oncol Biol Phys 2006, 65(July (3)):907-916.
54. Mok H., Crane C.H., Palmer M.B., et al. Intensity modulated radiation therapy (IMRT): differences in target volumes and improvement in clinically relevant doses to small bowel in rectal carcinoma. Radiat Oncol 2011, 6(June (8)):63.
55. Arbea L., Martinez-Monge R., Diaz-Gonzalez J.A., et al. Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial. Int J Radiat Oncol Biol Phys 2012, 83(June (2)):587-593.
56. Aristu J.J., Arbea L., Rodriguez J., et al. Phase I-II trial of concurrent capecitabine and oxaliplatin with preoperative intensity-modulated radiotherapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2008, 71(July (3)):748-755.
57. Ballonoff A., Kavanagh B., McCarter M., et al. Preoperative capecitabine and, accelerated intensity-modulated radiotherapy in locally advanced rectal cancer: a phase II trial. Am J Clin Oncol Cancer Clin Trials 2008, 31(June (3)):264-270.
58. Garofalo M., Moughan J., Hong T., et al. RTOG 0822: a phase H study of preoperative (PREOP) chemoradiotherapy (CRT) utilizing imrt in combination with capecitabine (C) and oxaliplatin (O) for patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2011, 81(2):S3-S4.
59. Arbea L., Moreno M., Rodriguez J., et al. Four-week neoadjuvant intensity modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a single institution experience with long-term follow-up. Int J Radiat Oncol Biol Phys 2012, 84(November (3)):S347.